No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TAK Takeda Pharmaceutical
- 13.230
- -0.150-1.12%
Close Apr 24 16:00 ET
41.87BMarket Cap36.75P/E (TTM)
13.330High13.210Low924.53KVolume13.320Open13.380Pre Close12.24MTurnover0.03%Turnover Ratio20.35P/E (Static)3.16BShares16.77352wk High0.96P/B40.58BFloat Cap13.11052wk Low0.63Dividend TTM3.07BShs Float20.779Historical High4.77%Div YieldTTM0.90%Amplitude11.808Historical Low13.243Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Top Gap Ups and Downs on Wednesday: TSLA, TXN, BSX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Neurocrine Succeeds in Mid-stage Trial for Takeda-partnered Depression Drug
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with major depressive disorder (MDD). In 2020, Neurocrine Biosc
TDK, Murata Manufacturing, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|-------|-------|＜3543＞|Komeda HD |SMBC Nikko |3000 yen |<4502＞|Takeda Pharmaceutical | Yamato | 4200 yen | 4500 yen |＜6268＞|Nabtesco | Tokai
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○ Purchase conversion stock list market code stock name closing price SAR Tokyo Stock Exchange Prime ＜2053＞ Chubu Feed 1173 1080 ＜2109＞ DM Mitsui Sugar 3025 2937 ＜2266＞ Rokko Butter 1453 1395 ＜2294＞ Kakiyasu Main Store 3180 3090 ＜2590＞ dyDo
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn's Disease Therapy
Takeda Pharmaceutical (TYO:4502) received the US Food and Drug Administration's approval for the subcutaneous administration of Entyvio, a maintenance therapy for adults with moderate to severe Crohn'
Comments
Update
$Takeda Pharmaceutical(TAK.US$ Takeda Says Primary And Key Secondary Endpoints Were Met In Narcolepsy Type 1 Phase 2b Trial;
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...
ColumnsRevolutionizing Healthcare: The Impressive Emergence of Artificial Intelligence in Medical Applications
The emergence of artificial intelligence (AI) in healthcare is transforming the medical industry by improving research, diagnoses, and treatment outcomes, and even drug discovery.
Let's take a look at a few of the different types of artificial intelligence and healthcare industry benefits that can be derived from their use.
The Competition to Discover the First Drug with AI
Insilico Medicine, ...
Let's take a look at a few of the different types of artificial intelligence and healthcare industry benefits that can be derived from their use.
The Competition to Discover the First Drug with AI
Insilico Medicine, ...
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg